Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis

YJ Suh, H Hong, M Ohana, F Bompard, MP Revel… - Radiology, 2021‏ - pubs.rsna.org
Background The association of pulmonary embolism (PE) with deep vein thrombosis (DVT)
in patients with coronavirus disease 2019 (COVID-19) remains unclear, and the diagnostic …

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

KKW To, S Sridhar, KHY Chiu, DLL Hung… - Emerging microbes & …, 2021‏ - Taylor & Francis
Without modern medical management and vaccines, the severity of the Coronavirus
Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) …

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2022‏ - thelancet.com
Background Casirivimab and imdevimab are non-competing monoclonal antibodies that
bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike …

[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England …, 2022‏ - pmc.ncbi.nlm.nih.gov
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …

Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury

KE Swenson, ER Swenson - Critical care clinics, 2021‏ - pmc.ncbi.nlm.nih.gov
The pathophysiology of acute respiratory distress syndrome (ARDS) is marked by
inflammation-mediated disruptions in alveolar-capillary permeability, edema formation …

Long-term lung abnormalities associated with COVID-19 pneumonia

JP Kanne, BP Little, JJ Schulte, A Haramati… - Radiology, 2022‏ - pubs.rsna.org
In the 3rd year of the SARS-CoV-2 pandemic, much has been learned about the long-term
effects of COVID-19 pneumonia on the lungs. Approximately one-third of patients with …

[HTML][HTML] Histopathological findings and clinicopathologic correlation in COVID-19: a systematic review

S Caramaschi, ME Kapp, SE Miller, R Eisenberg… - Modern Pathology, 2021‏ - Elsevier
The severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) pandemic has had
devastating effects on global health and worldwide economy. Despite an initial reluctance to …

[HTML][HTML] BCG vaccination provides protection against IAV but not SARS-CoV-2

E Kaufmann, N Khan, KA Tran, A Ulndreaj, E Pernet… - Cell reports, 2022‏ - cell.com
Since the vast majority of species solely rely on innate immunity for host defense, it stands to
reason that a critical evolutionary trait like immunological memory evolved in this primitive …

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2022‏ - thelancet.com
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …

The pulmonary pathology of COVID-19

H Bösmüller, M Matter, F Fend, A Tzankov - Virchows Archiv, 2021‏ - Springer
The lung is the main affected organ in severe coronavirus disease 2019 (COVID-19) caused
by the novel coronavirus SARS-CoV-2, and lung damage is the leading cause of death in …